CTNM Stock Overview
A clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Contineum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.53 |
| 52 Week High | US$22.00 |
| 52 Week Low | US$12.33 |
| Beta | 0 |
| 11 Month Change | -12.94% |
| 3 Month Change | -21.37% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.65% |
Recent News & Updates
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation
Oct 07
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Jun 13Shareholder Returns
| CTNM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 9.2% | 4.2% | 2.0% |
| 1Y | n/a | 13.7% | 32.4% |
Return vs Industry: Insufficient data to determine how CTNM performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CTNM performed against the US Market.
Price Volatility
| CTNM volatility | |
|---|---|
| CTNM Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTNM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CTNM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 31 | Carmine Stengone | www.contineum-tx.com |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Contineum Therapeutics, Inc. Fundamentals Summary
| CTNM fundamental statistics | |
|---|---|
| Market cap | US$395.95m |
| Earnings (TTM) | -US$28.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.0x
P/E RatioIs CTNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTNM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.89m |
| Earnings | -US$28.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CTNM perform over the long term?
See historical performance and comparison